Patients with metastatic NSCLC harboring KRAS hotspot mutations at codon G12 and those without KRAS hotspot mutations had similar OS (27.9 months [95% CI, 14.2-41.5 months] versus 27.2 months [95% CI, 22.3-32.1 months]; p=0.63) from initial metastasis diagnosis and (9.2 months [95% CI, 5.9-12.5 months] versus 8.5 months [95% CI, 4.2-12.8 months]; p=0.73) from initial phase I clinic visit. Here, KRAS is linked to non-small cell lung carcinoma.